Colorado Life Science Deal Flow Series A Companies: GlobeImmune Initiates Phase II Study

<body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/platform.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar.g?targetBlogID\x3d14319979\x26blogName\x3dColorado+Life+Science+Deal+Flow+Serie...\x26publishMode\x3dPUBLISH_MODE_BLOGSPOT\x26navbarType\x3dBLUE\x26layoutType\x3dCLASSIC\x26searchRoot\x3dhttps://seriesacompanies.blogspot.com/search\x26blogLocale\x3den_US\x26v\x3d2\x26homepageUrl\x3dhttp://seriesacompanies.blogspot.com/\x26vt\x3d1866957673157180849', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe" }); } }); </script>

Thursday, June 08, 2006

GlobeImmune Initiates Phase II Study

GlobeImmune, Inc. announced the initiation of a Phase II clinical trial of GI-4000, for the treatment of early-stage pancreas cancer. GI-4000 is designed to activate the immune system against cancer cells containing a mutated protein called Ras that is found in 80-90% of pancreas tumors. In a recently completed Phase 1 study of end-stage pancreas and colorectal cancer patients, GI-4000 was generally well-tolerated across the full range of doses tested.

Read the Red Herring Top 100 Start-up Companies in America article on GlobeImmune here.

0 Comments: